Vol. 7, Issue 2, Part H (2025)

Methicillin-resistant Staphylococcus aureus (MRSA) remains a major global cause of acute bacterial skin and skin structure infections (ABSSSI), posing challenges due to rising resistance, treatment failures, and the need for prolonged intravenous therapy. Traditional agents such as vancomycin and daptomycin require daily dosing, extended hospitalization, increasing healthcare burden. Dalbavancin, a long-acting lipoglycopeptide, has emerged as a significant advancement with its excellent long half-life, potent bactericidal activity, and convenient once-weekly or single-dose regimen. Clinical trials and real-world evidence consistently demonstrate its non-inferiority to conventional therapies, excellent tolerability, and strong activity against MRSA. Its ability to reduce inpatient stay, avoid central-line complications, and support outpatient treatment makes it a valuable tool in antimicrobial stewardship. Thie following review highlights the dosing, PK/PD, therapeutic benefits, safety profile, and expanding clinical applications of dalbavancin in the evolving management of MRSA and skin infections.